Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Taro-methylphenidate ER
- Development stage
- Unknown
- Lead developer
- Sun Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Taro-Methylphenidate ER is a small molecule, extended-release oral tablet developed and marketed by Sun Pharma Canada Inc. (a subsidiary of Sun Pharmaceutical Industries Limited). Its active ingredient is methylphenidate hydrochloride, a central nervous system (CNS) stimulant. The drug acts by inhibiting the dopamine and norepinephrine reuptake transporters (DAT and NET), thereby increasing monoamine neurotransmitter availability in the brain. It is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children (ages 6–12), adolescents (13–18), and adults (>18 years of age). Taro-Methylphenidate ER is the first and only bioequivalent to the brand-name drug Concerta® that utilizes an osmotic delivery system (OROS), providing controlled, once-daily release of the drug over approximately 12 hours.
- Brand names
- Taro-Methylphenidate ER
- Other names
- methylphenidate ERmethylphenidate hydrochloride extended-release
02
Targets
SERT (Sodium-dependent serotonin transporter)DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on Taro-methylphenidate ER.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Taro-methylphenidate ER.